Gilead Sciences and Merck recently ended a Phase 3 lung cancer study testing Trodelvy plus Keytruda in untreated metastatic non-small cell lung cancer after the trial did not meet its primary progression-free survival endpoint, despite showing only a numerical improvement not reaching statistical significance and an unlikely significant overall survival benefit.
The same companies reported positive results from two Phase 3 trials of an investigational once-weekly HIV treatment combination (islatravir and lenacapavir) that maintained viral suppression comparable to the standard daily Biktarvy regimen, which is seen as a significant step toward long-acting, convenient HIV therapy.
Sources:
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy ...
Trodelvy, Approved for Breast Cancer, Receives FDA Breakthrough ...
Gilead ADC medicine misses goal in closely watched lung cancer ...
Gilead and Merck Announce Phase 2 Data Showing a Treatment ...
For HCP's | Trodelvy® (sacituzumab govitecan-hziy) Combination ...
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
Gilead and Merck Announce Phase 2 Data Showing a ...
Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials
Gilead's trial of Trodelvy for NSCLC misses primary endpoint